Monitoring and Surveillance of Patients with Gastroenteropancreatic Neuroendocrine Tumors Undergoing Radioligand Therapy

被引:2
|
作者
Halfdanarson, Thorvardur R. [1 ]
Mallak, Nadine [2 ]
Paulson, Scott [3 ]
Chandrasekharan, Chandrikha [4 ]
Natwa, Mona [5 ]
Kendi, Ayse Tuba [1 ]
Kennecke, Hagen F. [6 ]
机构
[1] Mayo Clin, Rochester, MN 55905 USA
[2] Oregon Hlth & Sci Univ, Div Mol Imaging & Therapy, Portland, OR 97239 USA
[3] Texas Oncol, Dallas, TX 75230 USA
[4] Univ Iowa Carver, Coll Med, Iowa City, IA 52242 USA
[5] NYU, Langone Hlth, New York, NY 10016 USA
[6] Providence Canc Inst Franz Clin, Portland, OR 97213 USA
关键词
radioligand therapy; peptide receptor radionuclide therapy; neuroendocrine tumor; response; monitoring; surveillance; positron emission tomography; PET; imaging; somatostatin receptor; RECEPTOR RADIONUCLIDE THERAPY; SOCIETY CONSENSUS GUIDELINES; GA-68-DOTATATE PET/CT; MEDICAL-MANAGEMENT; LU-177-DOTATATE; SURVIVAL; PRRT; HEPATOTOXICITY; Y-90-DOTATOC; PREDICTION;
D O I
10.3390/cancers15194836
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Radioligand therapy with [177Lu]Lu-DOTA-TATE is a therapeutic option for adult patients with somatostatin-receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Patients undergoing radioligand therapy require diligent monitoring and surveillance. While published guidelines can provide guidance on general approaches to care, GEP-NETs are heterogeneous and the guidelines can be difficult to apply in individual and complex cases. In this article, we discuss emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving radioligand therapy for GEP-NETs as well as our own best practices. We offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.Abstract Radioligand therapy (RLT) with [177Lu]Lu-DOTA-TATE is a standard of care for adult patients with somatostatin-receptor (SSTR)-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Taking advantage of this precision nuclear medicine approach requires diligent monitoring and surveillance, from the use of diagnostic SSTR-targeted radioligand imaging for the selection of patients through treatment and assessments of response. Published evidence-based guidelines assist the multidisciplinary healthcare team by providing acceptable approaches to care; however, the sheer heterogeneity of GEP-NETs can make these frameworks difficult to apply in individual clinical circumstances. There are also contradictions in the literature regarding the utility of novel approaches in monitoring and surveilling patients with GEP-NETs receiving RLT. This article discusses the emerging evidence on imaging, clinical biochemistry, and tumor assessment criteria in the management of patients receiving RLT for GEP-NETs; additionally, it documents our own best practices. This allows us to offer practical guidance on how to effectively implement monitoring and surveillance measures to aid patient-tailored clinical decision-making.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] Update on gastroenteropancreatic neuroendocrine tumors
    Andreasi, Valentina
    Partelli, Stefano
    Muffatti, Francesca
    Manzoni, Marco F.
    Capurso, Gabriele
    Falconi, Massimo
    DIGESTIVE AND LIVER DISEASE, 2021, 53 (02) : 171 - 182
  • [42] Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important
    Xi-Feng Jin
    Matilde P. Spampatti
    Christine Spitzweg
    Christoph J. Auernhammer
    Reviews in Endocrine and Metabolic Disorders, 2018, 19 : 145 - 158
  • [43] State of the Art in Endoscopic Therapy for the Management of Gastroenteropancreatic Neuroendocrine Tumors
    Papaefthymiou, Apostolis
    Laskaratos, Faidon-Marios
    Koffas, Apostolos
    Manolakis, Anastasios
    Gkolfakis, Paraskevas
    Coda, Sergio
    Sodergren, Mikael
    Suzuki, Noriko
    Toumpanakis, Christos
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (07) : 1014 - 1034
  • [44] Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important
    Jin, Xi-Feng
    Spampatti, Matilde P.
    Spitzweg, Christine
    Auernhammer, Christoph J.
    REVIEWS IN ENDOCRINE & METABOLIC DISORDERS, 2018, 19 (02): : 145 - 158
  • [45] Treatment of gastroenteropancreatic neuroendocrine tumors
    Ploeckinger, U.
    Wiedenmann, B.
    VIRCHOWS ARCHIV, 2007, 451 (Suppl 1) : S71 - S80
  • [46] Biomarkers of gastroenteropancreatic neuroendocrine tumors
    d'Herbomez, Michele
    Coppin, Lucie
    Bauters, Catherine
    Carnaille, Bruno
    Do Cao, Christine
    CORRESPONDANCES EN METABOLISMES HORMONES DIABETES ET NUTRITION, 2016, 20 (07): : 174 - 177
  • [47] Quality Of Life in Patients with Neuroendocrine Gastroenteropancreatic Tumors Treated with Peptide Receptor Radionuclide Therapy
    Georgakopoulos, A.
    Liotsou, T.
    Chatziioannou, S. N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S691 - S691
  • [48] Gastroenteropancreatic neuroendocrine tumors. Diagnosis and therapy in nuclear medicine
    Haug, A. R.
    Bartenstein, P.
    INTERNIST, 2012, 53 (02): : 161 - 166
  • [49] Hypovitaminosis D in patients with neuroendocrine tumors undergoing SSA therapy
    Nosakova, L.
    Banovcin, P.
    Uhrik, P.
    Pindura, M.
    Hyrdel, R.
    JOURNAL OF NEUROENDOCRINOLOGY, 2021, 33 : 142 - 142
  • [50] State of the Art in Endoscopic Therapy for the Management of Gastroenteropancreatic Neuroendocrine Tumors
    Apostolis Papaefthymiou
    Faidon-Marios Laskaratos
    Apostolos Koffas
    Anastasios Manolakis
    Paraskevas Gkolfakis
    Sergio Coda
    Mikael Sodergren
    Noriko Suzuki
    Christos Toumpanakis
    Current Treatment Options in Oncology, 2022, 23 : 1014 - 1034